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Spotty Liver Disease (SLD) has occurred for decades in Australia and possibly over the world, 
with Campylobacter hepaticus being the bacteria identified only recently as the causal agent 
(Crawshaw et al., 2015; Van et al., 2016; Van et al., 2017; Kotiw et al., 2018).  The disease 
appears to largely affect layer chickens of free-range or barn systems.  SLD can affect any age 
flock during its first occurrence on a farm, although once established on a farm it occurs almost 
exclusively in flocks at peak of lay.  Egg production can decrease in the flock by 10-35%, and 
mortality increase by 10-15% (Crawshaw and Young, 2003; Burch, 2005; Grimes and Reece, 
2011), although these extremes are not always the case.  Dead and sick/cull birds have 
characteristic small, white-grey and/or red spots on the liver, which can also be swollen with a 























Figure 1A: Abnormal liver from a layer chicken infected with SLD.  Note excess pericardial 
fluid, hepatomegaly, and fibrin at the base of the liver lobe.  1B: erythematous ova of a layer that 
died of SLD.  
 
The financial cost of this disease is significant and can vary from flock-to-flock. Across 55 
recent SLD outbreaks in peak-of-lay birds of flocks in Australia, the disease has been calculated 
to cost between $0.5/bird in the flock to $4.29/bird in the flock.  This is $5,000-$42,900/10,000 
birds.  The largest factor identified to affect cost of the disease was mortality; as dead birds 
obviously don’t lay eggs for the rest of the flock life.  Other factors calculated in cost of the 
 
disease were eggs lost during the egg production drop, costs of in-feed or in-water additives 
trialled to prevent SLD, and any treatments given to the flock.  Extra labour costs were not 
calculated in these figures, but feed savings of dead birds were.  Interestingly, across the vast 
number of in-feed and in-water additives trialled (probiotics, prebiotics, acids, clays, essential 
oils and others), none prevented, or significantly reduced the mortality associated with SLD in 
flocks.  The effect of additives was somewhat hard to analyse, as mortality from SLD was 
always lower in the cooler months of winter.      
 
The above-mentioned financial cost of the disease, along with the welfare implications, 
antibiotic use and effect on staff general well-being, easily justifies the effort required to 
undertake vaccine trials against SLD in Australia.   
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45 Hy-Line brown commercial pullets of 16 weeks of age were used for the vaccine dosage and 
challenge trials.   All chickens were pre-screened for C. hepaticus via PCR of rectal swabs and 
leg banded and wing tagged for identification. 
 
Chickens were housed in four climate-controlled rooms, with groups of birds being: 
- 9 x negative controls (no vaccination or challenge) 
- 9 x killed vaccine A + C. hepaticus oral challenge 
- 9 x killed vaccine B + C. hepaticus oral challenge 
- 9 x killed vaccine C + C. hepaticus oral challenge  
- 9 x positive controls (vaccine adjuvant only + C. hepaticus oral challenge)  
 
Chickens were vaccinated at 16 and 18 wks of age, and challenged at 21 wks of age.  No dead or 
morbid birds occurred during the trial.  All chickens were culled and sampled 13 days post 
challenge.  Livers were scored between 0-5 for gross pathological lesions, with 5 being 
comparable to that of an SLD dead bird in a field outbreak.  Bile and liver samples were cultured 
on sheep blood agar and in Bolton broth. Bile, liver, duodenal, jejunal, caecal and rectal samples 
were tested for C. hepaticus on PCR.  Liver samples were collected in formaldehyde for 
histopathology.   
 
Of the positive control birds, 6/9 (67%) had gross pathological changes on the livers, consistent 
with various stages of SLD.  These livers were scored between 1 and 4, with examples shown in 
Figure 2.  Of the 27 vaccinated birds, only 2 birds from one of the vaccine groups had gross 
pathological changes consistent with SLD.  These livers were both given score 1, and are shown 








On culture, positive control and vaccinated bird groups had some amount of growth from the bile 
and liver, with bile being most fruitful.  Growth from the bile of the positive control birds was 
significantly higher than that seen with two out of the three groups of vaccinated birds.  Negative 
control birds had no growth.   
 
On PCR, birds from each of the positive control and vaccinated groups had C. hepaticus present 
in all organ samples: bile, liver, duodenum, jejunum, caecum and rectum.  Statistically, the 
positive control group had significantly more of the organism in the caecum than two of the 


















Figure 2:  Examples of gross pathological findings of positive control chickens.  The liver on the 
















Figure 3:  Gross pathological findings of the two vaccinated birds.  Arrows denote minor 
changes 
 
Microscopically, eight out of nine liver samples from the positive control group had inflammatory 
lesions, ranging from mild to classical SLD lesions. All liver samples from the negative controls and 
vaccinated birds had normal histopathology.    
 
 
In conclusion, results of this small-scale vaccine trial have warranted further trials in the 
field/commercial setting.  The vaccine adjuvant used needs to be approved by APVMA to 
progress.   
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In an aviary rearing shed of 40,000 chickens, 20,000 birds were vaccinated twice at 12 and 16 
weeks of age with an autogenous C. hepaticus killed vaccine.  The isolates used to prepare this 
vaccine were derived from virulent outbreaks of SLD at the free-range farm where the trial took 
place, and where SLD occurs in every flock around peak of lay.  The remaining 20,000 birds in 
the rearing shed were left as unvaccinated controls.   
 
All rearing birds from this shed were shifted to the layer house at 16 weeks of age.  Half the 
birds were on one side of the shed, and half on the other, with mesh separating the two.  Egg 
production and mortality were recorded separately for the two groups.  Birds were given access 
to the range at 20 weeks of age. 
 
The first signs of SLD occurred in the shed at 27 weeks of age.  Given the size of the shed, the 
outbreak lasted for 6 weeks, when production recovered to standard and mortalities from SLD 
stopped.   
 
Final figures from the outbreak were that both vaccinated and unvaccinated decreased in 
production by 11% and then recovered, and mortality in the two groups from SLD was 3.09% 
and 3.67%, in favour of the control birds.  Hence, in this case, the vaccine was not deemed to 
protect the birds from SLD.  Interestingly though, serology showed that in the weeks after being 
vaccinated, all the birds, both vaccinated and unvaccinated, seroconverted.   
 
This trial is currently being repeated in another flock, where, at the time of publication of this 





Burch, D., 2005. Avian vibrionic hepatitis in laying hens. Vet. Rec. 157, 528 
 
Crawshaw, T.R., Chanter, J.I., Young, S.C., Cawthraw, S., Whatmore, A.M., Koylass, M.S., 
Vidal, A.B., Salguero, F.J., Irvine, R.M., 2015.  Isolation of a novel thermophilic Campylobacter 
from cases of spotty liver disease in laying hens and experimental reproduction of infection and 
microscopic pathology. Vet Microbiol. 179, 315-321. 
 
 
Crawshaw, T., Young, S., 2003. Increased mortality on a free-range layer site. Vet. Rec. 153, 
664. 
 
Grimes, T., Reece, R. 2011. Spotty liver disease-an emerging disease in free-range egg layers in 
Australia. In:  Proceedings 60th Western Poultry Disease Conference, Sacramento, CA, 53-56. 
 
Kotiw, M., Courtice, J., Mahdi, L., Wei, C., Ahmad T. & Groves P., 2018.  Spotty Liver Disease 
A South East Queensland Perspective. In: Proceedings Poultry Information Exchange 
Australasian Milling Conference 2018, Gold Coast, Australia, 149-152.   
 
Van, T.T., Elshagmani, E., Gor, M.C., Scott, P.C., Moore, R.J., 2016. Campylobacter hepaticus 
sp. nov., isolated from chickens with spotty liver disease. Int. J. Syst. Evol. Microbiol.  66, 4518-
4524. 
 
Van, T.T., Elshagmani, E., Gor, M.C., Anwar, A., Scott, P.C., Moore, R.J., 2017. Induction of 
spotty liver disease in layer hens by infection with Campylobacter hepaticus. Vet. Microbiol.  
199, 85-90. 
 
 
